Last updated 2026-07-26
TL;DR
Human data on CJC-1295 comes mainly from one 2006 study (Teichman et al., 65 subjects, up to 6 months) showing sustained GH and IGF-1 increases with the DAC version. No published human trials exist for CJC-1295 without DAC, and none test it combined with ipamorelin. Everything beyond that single trial is extrapolation or forum anecdote.
What human studies actually exist for CJC-1295?
There is really one primary human study people are citing when they talk about CJC-1295, and it's worth being precise about what it did and didn't show. The study is Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006, titled "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I (IGF-I) Secretion by CJC-1295, a Long-Acting Growth-Hormone-Releasing Hormone Analog" [1]. The trial enrolled 65 healthy adult subjects. It tested single ascending doses (up to 60 or 100 mcg/kg depending on the arm) and then multiple doses of the drug company's DAC-conjugated version over a period of weeks to months. Some subjects were followed for up to six months. The study reported that a single dose raised GH levels for 6 days or more and that repeated dosing (weekly or twice weekly) sustained mean GH levels at up to 2 to 10 times baseline and raised IGF-I by roughly 1.5 to 3 times baseline, sustained across the dosing period [1]. That is the entire published human clinical trial base. There is no large multi-center trial, no long-term (multi-year) safety follow-up, and no published human RCT of CJC-1295 without DAC (the shorter-half-life version, sometimes called Mod GRF 1-29 in gray-market circles). If someone tells you "studies show CJC-1295 does X," ask them which study, because there's really only one to point to, and it was run by the company that developed the drug, ConjuChem, as part of its own development program. Worth noting: this was a Phase 1/2-style safety and pharmacodynamic study, not a large efficacy trial for a specific disease indication. The company's clinical program did not lead to FDA approval, and CJC-1295 remains an unapproved compound in the US, not a prescribed drug for any condition.
What did the Teichman 2006 study actually measure and conclude?
The study measured GH and IGF-I blood levels after single and multiple doses of DAC-CJC-1295, plus basic safety and tolerability data (adverse events, injection site reactions, vital signs). The authors' own conclusion, stated in the abstract, was that "CJC-1295 has the potential, with infrequent dosing, to correct GH insufficiency in GH-deficient adults" and that it produced "sustained, dose-dependent increases in GH and IGF-I" [1]. That's a fairly specific, modest claim: a pharmacodynamic proof-of-concept in healthy adults, framed around a future indication (adult GH deficiency), not a general performance, fat-loss, or anti-aging claim. The study did not measure body composition changes, strength, sleep quality, skin, or any of the outcomes that show up constantly in forum threads. It measured hormone levels in blood. Adverse events reported included injection site reactions (flushing and pain being the most common, consistent with GHRH-class peptides generally) and some reports of flushing of the face. No serious adverse events tied to the drug were reported in the paper, but again, this is 65 people over a few months, which is not enough to catch rare or long-term effects. A study this size is built to answer "does this raise GH and is it tolerable short-term," not "is this safe over 5 years" or "does this help me lose fat."
Does CJC-1295 have separate human data for the DAC and no-DAC versions?
No. This is one of the most commonly misunderstood points, so it's worth being direct: the Teichman 2006 trial tested the DAC-conjugated molecule, the version designed to bind serum albumin and extend its half-life to roughly 6 to 8 days [1]. The non-DAC version, a shorter GHRH(1-29) analogue with a plasma half-life measured in minutes, was not the subject of that published human trial. The no-DAC version's pharmacology is inferred from older, separate research on GHRH(1-29) analogues (modified growth hormone releasing factor fragments) done in the 1980s and 1990s, not from a dedicated CJC-1295-no-DAC human trial [2]. That's a real gap. People using no-DAC CJC-1295 today are relying on a chain of inference: this fragment resembles GHRH(1-29) analogues studied decades ago, which behaved a certain way, therefore this behaves similarly. That's a reasonable pharmacological argument, but it is not the same as a dedicated clinical trial on the actual product being sold. If you want the full comparison of half-life, dosing frequency, and practical tradeoffs between the two forms, that's covered in detail on the CJC-1295 DAC or no-DAC comparison. For human studies purposes, the short version is: DAC has a real published trial behind it; no-DAC is riding on analogy.
Is there any human research on CJC-1295 combined with ipamorelin?
No published human trial has tested CJC-1295 and ipamorelin together as a combined protocol. This pairing is extremely common in gray-market and compounding contexts, and the rationale is pharmacologically coherent, but it has not been tested as a combination in a clinical trial. The logic behind pairing them comes from separate lines of research on two different receptor pathways. CJC-1295 acts on the GHRH receptor, the pathway your hypothalamus uses to tell the pituitary to release GH. Ipamorelin acts on the ghrelin receptor (also called the GH secretagogue receptor), a separate pathway that also stimulates GH release and has been studied on its own, including in older work on ghrelin-mimetic peptides showing that combining a GHRH analogue with a ghrelin-receptor agonist produces a larger GH pulse than either alone in some experimental settings [3]. That combination effect is documented for the GHRH-plus-ghrelin-agonist class in general physiological studies, not for this specific branded pairing in a dedicated clinical trial. So the honest statement is: there's real receptor biology explaining why people stack these two, and there's older research on the general concept of combining a GHRH pathway agonist with a ghrelin pathway agonist. There is not a study that enrolled human subjects, gave them CJC-1295 plus ipamorelin specifically, and reported outcomes. Anyone claiming a specific numeric outcome from "the CJC-1295 and ipamorelin stack" is not quoting a study. They're quoting forum consensus or a supplier's marketing copy.
What does the research say about CJC-1295 dosing and how long effects last?
The Teichman 2006 study is again the main source here. It tested single doses ranging up to 100 mcg/kg and found that a single 60 mcg/kg or 100 mcg/kg dose elevated mean GH levels for at least 6 days, with IGF-I staying elevated for about 9 to 11 days after a single dose [1]. In the multiple-dose arms, subjects received doses roughly weekly or twice weekly over the study period, and GH and IGF-I stayed elevated throughout dosing without an obvious drop-off in effect (no significant tachyphylaxis was reported over the study duration) [1]. That single-dose data is specific to the DAC version's long half-life. It does not describe how the shorter-acting no-DAC version behaves, since that variant clears the body in roughly 30 minutes and needs much more frequent dosing (commonly once or twice daily in non-clinical use patterns) to maintain any pulse pattern. For a full walkthrough of how these dosing patterns translate to actual injection schedules, see the site's dosing guidance and injection site rotation guide. One concrete, quotable number worth pulling out: the study's own abstract describes IGF-I increases of "approximately 1.5- to 3-fold" over baseline sustained across multi-dose treatment [1]. That's a specific, real range from a real trial, and it's a fairer thing to quote than the vague "boosts GH" language that circulates online.
What did earlier GHRH research show before CJC-1295 was developed?
CJC-1295 didn't appear from nowhere. It's built on decades of GHRH(1-29) research, since the first 29 amino acids of natural GHRH retain full biological activity while being easier to synthesize and modify. Academic and pharmaceutical interest in GHRH analogues goes back to the 1980s, following the 1982 identification of human GHRH itself [4]. Sermorelin, a GHRH(1-29) analogue, actually received FDA approval decades ago as Geref, marketed for diagnostic testing of GH reserve and for treatment of certain GH deficiencies in children, though it was later discontinued from the US market for commercial reasons, not safety findings [5]. Sermorelin's approval history matters here because it's the closest thing to a genuinely FDA-reviewed precedent in this drug class, and its short half-life (about 10 to 20 minutes) is part of why researchers wanted a longer-acting version, which is what CJC-1295's DAC technology was designed to solve. That history explains the mechanism CJC-1295 relies on (GHRH receptor agonism) but it does not transfer sermorelin's approval or safety record onto CJC-1295. CJC-1295 itself never completed the clinical development and approval process; ConjuChem's broader drug pipeline had financial and developmental setbacks in the years following the 2006 study, and no CJC-1295 product reached FDA approval or ongoing marketed status.
What are the known or reported side effects in human data?
From the Teichman 2006 trial, the reported adverse events were mostly mild and local: injection site reactions, flushing, and some reports of redness or discomfort at the injection site [1]. No serious drug-related adverse events were reported in that paper's dataset of 65 subjects over the study period. Beyond that single trial, side effect information for CJC-1295 in humans is thin. There's no large safety database, no adverse event reporting system tracking it (because it isn't an approved drug), and no long-term data on cardiovascular, oncologic, or metabolic risk with sustained GH/IGF-I elevation from this specific compound. What we do know from the much larger and older literature on chronically elevated GH and IGF-I (largely from acromegaly research, a naturally occurring condition of GH excess) is that sustained high GH/IGF-I is associated with cardiovascular changes, joint and soft tissue changes, and insulin resistance over years [6]. That's not a CJC-1295 finding, it's a caution drawn from the physiology of what chronically high GH/IGF-I does in the body generally, and it's a reasonable thing to weigh even though nobody has run the equivalent long-term study on this specific peptide. The honest bottom line: short-term tolerability in the one real trial looks unremarkable. Long-term risk is unknown, not because it's been studied and found safe, but because it hasn't been studied at all past a few months in 65 people.
Is CJC-1295 FDA approved, and what does that mean for the human data question?
No. CJC-1295 is not an FDA-approved drug for any indication, in humans. It is commonly sold and shipped as a "research chemical" or research-use-only compound, which is a regulatory category, not a safety endorsement. The FDA's research-use-only framing means the product is explicitly not intended for human consumption according to the label, regardless of how it's actually used by buyers [7]. This matters for the human studies conversation because it means there's no post-marketing surveillance, no FDA-mandated reporting of adverse events tied to real-world use, and no batch-to-batch quality assurance requirement the way there would be for an approved drug. The one clinical trial that exists (Teichman 2006) was run under the sponsor's own development program, using pharmaceutical-grade material manufactured to trial standards, which is a different supply chain than what's typically available through research-chemical vendors today. If you're trying to line up a source with any oversight at all, a provider-reviewed pathway that routes through a licensed compounding pharmacy is a meaningfully different situation from an unregulated vendor, in terms of what's actually in the vial. CJC-1295 Co's how to get CJC-1295 guide walks through that distinction, and the sourcing page covers what a provider-reviewed listing actually verifies versus what it doesn't.
How does the CJC-1295 evidence base compare to other GH secretagogues?
| Sermorelin (GHRH 1-29) | Previously approved (Geref), later discontinued commercially | Multiple published trials supporting diagnostic and GH-deficiency use [5] | |
|---|---|---|---|
| CJC-1295 (DAC) | Not approved | One published trial, Teichman et al. 2006, 65 subjects, up to 6 months [1] | |
| CJC-1295 (no-DAC) | Not approved | No dedicated published human trial; inferred from older GHRH(1-29) analogue research [2] | |
| Tesamorelin | FDA approved (Egrifta) for HIV-associated lipodystrophy | Multiple Phase 3 RCTs supporting approval | |
| Ipamorelin | Not approved | Early-phase human pharmacodynamic studies exist but no large trial base [3] | The standout on this list is tesamorelin, which went through full Phase 3 development and FDA approval for a specific indication, backed by placebo-controlled trials with hundreds of patients . That's the kind of evidence density CJC-1295 simply doesn't have. It's a useful benchmark for what "well-studied in humans" actually looks like versus what CJC-1295 has, which is one solid but small proof-of-concept trial. |
It helps to see this next to compounds people often compare it against. The table below lines up the strength of human evidence, not the strength of the physiological effect. | Compound | FDA status | Primary human trial evidence |
What questions about CJC-1295 remain unanswered by human research?
A short, honest list. First, long-term safety past 6 months has never been studied in a published trial; everything past that window is extrapolation from GH physiology generally. Second, no trial has measured body composition, fat loss, lean mass, or exercise performance outcomes specifically from CJC-1295, so any claim about "burns fat" or "builds muscle" from CJC-1295 alone is not backed by the trial data, even though it's plausible given what elevated GH/IGF-I does generally. Third, the no-DAC version has never had its own dedicated human trial, so its actual pharmacokinetics in real users are inferred, not measured directly in a CJC-1295-no-DAC-specific study. Fourth, the ipamorelin combination has never been tested as a combination in a published human trial, so any specific claimed combined effect number is not from a study of that pairing. Fifth, sourcing and product consistency: a research chemical vendor's product is not the same pharmaceutical-grade material used in the 2006 trial, so even the DAC trial's tolerability findings don't automatically transfer to whatever is in a given vial from an unverified source. That's a supply chain question more than a science question, but it's one worth taking as seriously as the pharmacology, and it's covered in more practical detail in the site's guides on storage and shelf life and reconstitution.
Frequently asked questions
How many human studies have been done on CJC-1295?
Essentially one primary published clinical trial: Teichman et al., 2006, in the Journal of Clinical Endocrinology & Metabolism, with 65 healthy adult subjects followed for up to 6 months on the DAC-conjugated version. No large-scale, long-term, or multi-trial evidence base exists beyond that study and the older general GHRH(1-29) literature it builds on.
Was the CJC-1295 study peer reviewed?
Yes. Teichman et al. was published in the Journal of Clinical Endocrinology & Metabolism, a peer-reviewed endocrinology journal, in 2006. Peer review means the methodology and stated results passed editorial and reviewer scrutiny before publication, but it doesn't change the fact that it's one study of 65 people over a few months, which is a small evidence base by drug-approval standards.
Does CJC-1295 have FDA approval?
No. CJC-1295 has never received FDA approval for any human indication. It's typically sold as a research-use-only compound, a regulatory category meaning it's not approved or labeled for human consumption, regardless of how buyers actually use it. Sermorelin, a related GHRH fragment, was previously FDA approved as Geref before being discontinued commercially.
What is the difference between CJC-1295 with DAC and without DAC in the studies?
The published 2006 human trial tested the DAC version, which binds albumin and has a half-life of roughly 6 to 8 days. The no-DAC version, with a half-life of about 30 minutes, has never had its own dedicated human clinical trial; its expected behavior is inferred from older research on similar GHRH(1-29) fragment analogues, not measured directly.
Has CJC-1295 with ipamorelin been studied together in humans?
No. There's no published clinical trial testing the CJC-1295 and ipamorelin combination specifically. The pairing is common in practice because they act on two different receptors (GHRH receptor and ghrelin/GHSR), and older research on combining those receptor classes generally shows an additive GH response, but that's not the same as a trial of this specific stack.
What side effects showed up in the CJC-1295 human trial?
The 2006 Teichman study reported mostly mild, local effects: injection site reactions, flushing, and occasional redness or discomfort at the injection site. No serious drug-related adverse events were reported among the 65 subjects over the study's duration, but the trial was too small and short to detect rare or long-term risks.
How long does a single dose of CJC-1295 raise GH levels according to the study?
In the 2006 trial, a single dose of 60 or 100 mcg/kg of DAC-CJC-1295 raised mean GH levels for at least 6 days, with IGF-I staying elevated for roughly 9 to 11 days after that one dose, according to the study's reported pharmacodynamic data.
Does CJC-1295 help with fat loss or muscle gain based on the studies?
The published trial measured GH and IGF-I blood levels, not body composition, strength, or fat loss outcomes. Any fat-loss or muscle-gain claim about CJC-1295 specifically is extrapolated from what elevated GH/IGF-I generally does in other research, not from a direct measurement in a CJC-1295 trial.
Is CJC-1295 legal to buy in the United States?
It is not FDA approved as a drug and is generally sold labeled research-use-only, not for human use. Legal status for personal possession varies and depends on how it's sourced and marketed; a provider-reviewed pathway through a licensed compounding pharmacy is a materially different regulatory situation than buying from an unverified research-chemical vendor.
Who ran the original CJC-1295 clinical trial?
The study was conducted as part of ConjuChem's drug development program and published as Teichman et al. in the Journal of Clinical Endocrinology & Metabolism in 2006. ConjuChem developed the DAC (Drug Affinity Complex) technology used to extend the peptide's half-life.
How does CJC-1295's evidence compare to tesamorelin's?
Tesamorelin (brand name Egrifta) went through full Phase 3 clinical trials and received FDA approval for HIV-associated lipodystrophy, backed by placebo-controlled studies with hundreds of patients. CJC-1295 has one 65-person pharmacodynamic trial and no FDA approval, making tesamorelin's human evidence base substantially larger and more rigorous.
Why do people combine CJC-1295 with ipamorelin if it's not been studied together?
The rationale is mechanistic: CJC-1295 stimulates the GHRH receptor while ipamorelin stimulates a separate ghrelin receptor pathway, and older physiology research shows combining agonists from these two classes produces a larger GH pulse than either alone. That's a plausible biological argument, not evidence from a trial of this specific combination in humans.
Sources
- Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 DAC trial of 65 subjects showing sustained GH and IGF-I increases
- NCBI/PubMed, growth hormone-releasing hormone(1-29) analogue research: Older GHRH(1-29) analogue research underlying inferred pharmacology of no-DAC CJC-1295
- PubMed, ghrelin receptor agonist and GHRH combination GH response studies: Combining GHRH pathway and ghrelin receptor agonists produces additive GH release in physiological studies
- PubMed, Guillemin R et al., 1982, characterization of human GHRH: Human growth hormone-releasing hormone was identified and characterized in 1982
- FDA, Geref (sermorelin acetate) drug approval history: Sermorelin (Geref) was an FDA-approved GHRH(1-29) analogue later discontinued commercially
- NIH/NIDDK, acromegaly overview: Chronic GH/IGF-I excess is associated with cardiovascular, joint, and metabolic changes over time
- FDA, guidance on research-use-only labeled products: Research-use-only labeling means a product is not intended for human use regardless of the FDA-approval status of related devices/drugs